CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 2,040 enrolled
Drug / intervention
Dolutegravir / Lamivudine Pilldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04707326
NCT04707326N/AActive
CompareCT.gov

Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study.

Erasmus Medical Center·observational·Posted Jan 13, 2021·Updated Dec 20, 2024

In Brief

An observational study evaluating Dolutegravir / Lamivudine Pill for Hiv. Active but no longer recruiting, targeting 2,040 participants across 9 sites.

Detailed Summary

This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHiv
CountriesNetherlands
CollaboratorsMaasstad Hospital, Haaglanden Medical Centre, Catharina Ziekenhuis Eindhoven, Elisabeth-TweeSteden Ziekenhuis, Rijnstate Hospital, Admiraal de Ruyter Hospital, Spaarne Gasthuis, Medisch Spectrum Twente

Timeline

N/AActive
20202021202220232024202520262027
First PostedJan 13, 2021
Enrollment StartNov 1, 2019
Primary CompletionNov 1, 2023
Study CompletionNov 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 5.5 years ago

Interventions

Dolutegravir / Lamivudine Pilldrug

HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B